The aspartate aminotransferase‐to‐platelet ratio index (APRI), a tool with limited expense
and widespread availability, is a promising noninvasive alternative to liver biopsy for …

This article has been corrected. The original version (PDF) is appended to this article as a
supplement. Background: Many blood tests have been proposed as alternatives to liver …

Background Cirrhosis of the liver is the end stage of chronic liver disease. Among the many
liver disorders that can lead to cirrhosis, some progress rapidly (years) and others more …

The development of noninvasive markers of liver fibrosis is a clinical and research priority.
The aspartate aminotransferase‐to‐platelet ratio index (APRI) is a promising tool with limited …

Context Among adult patients with liver disease, the ability to identify those most likely to
have cirrhosis noninvasively is challenging. Objective To identify simple clinical indicators …

BACKGROUND: Liver biopsy is the reference standard for diagnosing the extent of fibrosis
in chronic liver disease; however, it is invasive, with the potential for serious complications …

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver
disease in American children. Noninvasive means to discriminate between NAFLD and …

Background The aspartate aminotransferase-to-platelet ratio index (APRI), a tool with limited
expense and widespread availability, is a promising noninvasive alternative to liver biopsy …

Background Recent animal studies have shown that platelets directly activate hepatic
stellate cells to promote liver fibrosis, whereas anti‐platelet agents decrease liver fibrosis. It …

Assessment of liver fibrosis is critical for successful individualized disease management in
persons with chronic hepatitis B (CHB) or chronic hepatitis C (CHC). We expanded and …